Patents Assigned to Ocata Therapeutics, Inc.
-
Publication number: 20170152481Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.Type: ApplicationFiled: July 6, 2016Publication date: June 1, 2017Applicant: Ocata Therapeutics, Inc.Inventors: Robert Lanza, Shi-Jiang Lu
-
Publication number: 20170121681Abstract: Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided.Type: ApplicationFiled: March 24, 2016Publication date: May 4, 2017Applicant: Ocata Therapeutics, Inc.Inventors: Robert Lanza, Shi-Jiang Lu
-
Patent number: 9410123Abstract: Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom.Type: GrantFiled: May 6, 2009Date of Patent: August 9, 2016Assignee: Ocata Therapeutics, Inc.Inventors: Robert Lanza, Shi-Jiang Lu
-
Publication number: 20160175362Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.Type: ApplicationFiled: September 17, 2015Publication date: June 23, 2016Applicant: Ocata Therapeutics, Inc.Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
-
Publication number: 20160115450Abstract: Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications.Type: ApplicationFiled: September 29, 2015Publication date: April 28, 2016Applicant: OCATA THERAPEUTICS, INC.Inventors: Robert Lanza, Shi-Jiang Lu
-
Publication number: 20160030490Abstract: Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicant: Ocata Therapeutics, Inc.Inventors: Robert P. Lanza, Shi-Jiang Lu, Wei Wang
-
Publication number: 20150366915Abstract: This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients.Type: ApplicationFiled: May 15, 2015Publication date: December 24, 2015Applicant: Ocata Therapeutics, Inc.Inventors: Roger Gay, Irina V. Klimanskaya, Robert P. Lanza
-
Patent number: 9193950Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: March 27, 2014Date of Patent: November 24, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Publication number: 20150328261Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: ApplicationFiled: April 21, 2015Publication date: November 19, 2015Applicant: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Patent number: 9181524Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: March 27, 2014Date of Patent: November 10, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Publication number: 20150313944Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.Type: ApplicationFiled: December 21, 2013Publication date: November 5, 2015Applicant: Ocata Therapeutics, Inc.Inventors: Qiang Feng, Shi-Jiang Lu, Robert P. Lanza
-
Publication number: 20150272994Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.Type: ApplicationFiled: February 23, 2015Publication date: October 1, 2015Applicant: Ocata Therapeutics, Inc.Inventors: Erin Anne Kimbrel, Robert P. Lanza, Jianlin Chu, Nicholas Arthur Kouris
-
Publication number: 20150209126Abstract: Methods for generating embryos using pluripotent stem cells are provided. The subject methods include methods for generating chimeric embryos, wherein only a subset of the cells of each embryo are genetically identical to the pluripotent stem cells used in the generation process. The subject methods also include methods for generating embryos that are identical or are essentially genetic clones of the pluripotent stem cells (e.g., the resulting embryos are substantially identical, genetically, to the pluripotent stem cells used in the generation process).Type: ApplicationFiled: April 9, 2015Publication date: July 30, 2015Applicant: Ocata Therapeutics, Inc.Inventor: Robert P. LANZA
-
Patent number: 9080150Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: May 22, 2012Date of Patent: July 14, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert Lanza
-
Patent number: 9045732Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: April 8, 2013Date of Patent: June 2, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Patent number: 9040038Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: April 8, 2013Date of Patent: May 26, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Patent number: 9040770Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: May 18, 2010Date of Patent: May 26, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina Klimanskaya, Robert Lanza
-
Patent number: 9040039Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: April 18, 2013Date of Patent: May 26, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Patent number: 8962321Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.Type: GrantFiled: November 30, 2012Date of Patent: February 24, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Erin Anne Kimbrel, Robert Lanza, Jianlin Chu, Nicholas Arthur Kouris
-
Patent number: 8961956Abstract: The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.Type: GrantFiled: May 30, 2013Date of Patent: February 24, 2015Assignee: Ocata Therapeutics, Inc.Inventors: Erin Anne Kimbrel, Robert Lanza, Jianlin Chu, Nicholas Arthur Kouris